Clinical Trials Logo

Clinical Trial Summary

Acute adenoviral conjunctivitis is a highly contagious, widespread endemic disease associated with frequent outbreaks, significant patient discomfort, lost productivity, and in some cases permanent visual compromise from long-term immune mediated sequelae. OKG-0301 is a novel ophthalmic solution with a potent ribonuclease that has broad-spectrum antiviral properties relevant for the treatment of acute adenoviral conjunctivitis. This randomized, double masked, multi-center Phase 2 study is being conducted entirely within Australia and is designed to support the safety and efficacy of OKG-0301 for the treatment of acute adenoviral conjunctivitis. The study intends to show superiority of OKG-0301 Ophthalmic Solution compared to vehicle for the primary efficacy endpoint of mean change from baseline in viral titre in patients with acute adenoviral conjunctivitis. Secondary efficacy endpoints including adenoviral eradication, clinical cure of acute adenoviral conjunctivitis, subepithelial infiltrates, other clinical signs and symptoms, and rate of cross-over infection to the other eye will also be assessed. Safety will also be evaluated.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03856645
Study type Interventional
Source Okogen
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 11, 2019
Completion date June 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT01532336 - Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis Phase 2
Terminated NCT02998554 - Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo Phase 3
Terminated NCT02998541 - Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo Phase 3
Completed NCT02472223 - Reducing Adenoviral Patient Infected Days N/A
Terminated NCT00901693 - An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis Phase 2
Withdrawn NCT03009799 - Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) Phase 2
Completed NCT00266734 - Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears N/A
Completed NCT03749317 - Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis Phase 2